AR 12

Drug Profile

AR 12

Alternative Names: AR-12; NSC D728209; OSU-03012

Latest Information Update: 07 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Acetate-CoA ligase inhibitors; Angiogenesis inhibitors; Apoptosis stimulants; Autophagy stimulants; HSP70 heat shock protein inhibitors; HSP90 heat-shock protein inhibitors; Molecular chaperone GRP78 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryptococcosis; Tularaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lymphoma; Solid tumours
  • Discontinued Bacterial infections; Cryptococcosis; Onychomycosis; Tularaemia; Viral infections

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics data from a preclinical trial in Viral infections (Zika virus infections) presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 22 Dec 2017 Arno Therapeutics terminates its license for AR 12 before December 2017
  • 22 Dec 2017 Discontinued - Preclinical for Bacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top